RT Journal
A1 Friedrich MJ
T1 EFfective malaria vaccine
JF JAMA
JO JAMA
YR 2011
FD December 21
VO 306
IS 23
SP 2553
OP 2553
DO 10.1001/jama.2011.1808
UL http://dx.doi.org/10.1001/jama.2011.1808
AB 
In the study, children in 2 age categories—6 to 12 weeks of age and 5 to 17 months of age—at 11 trial sites in 7 countries received either the RTS,S/AS01 Plasmodium falciparum vaccine or a nonmalaria comparator vaccine. The researchers found that 3 doses of the RTS,S/AS01 vaccine in the first 6000 of 8923 children in the older age category reduced the risk of children experiencing malaria and severe malaria by 56% and 47%, respectively, during the 12 months after vaccination. Efficacy and safety data from the younger age group are expected in 2012.